DX&VX Completes Patent Application for Second Oral Obesity Treatment Candidate Substance

DXVX announced on the 2nd that it has completed a patent application for its second new drug candidate for an oral obesity treatment based on GLP-1 (Glucagon-like peptide-1) receptor agonists.

The company stated that by completing the patent application for the second candidate following the one on the 26th of last month, it will accelerate the development speed to strengthen competitiveness in the obesity treatment market, which is expected to grow to over 100 trillion KRW globally by 2030.

Both patents filed by DXVX are based on low-molecular GLP-1RA (Glucagon-like peptide-1 receptor agonist) technology, but are expected to show differentiated effects through different compound structures and mechanisms of action. In this way, DXVX has opened the possibility of developing various low-molecular GLP-1RA compounds to provide personalized treatment tailored to individual patient characteristics.

The reason DXVX shows strong confidence in its development speed is that all the PhD-level researchers leading this drug development team come from Hanmi Pharmaceutical and Daewoong Pharmaceutical, possessing accumulated experience and know-how. The Dx&Vx New Drug Development Headquarters is staffed with experts experienced in the entire drug development cycle including synthesis, pharmacology/toxicology, clinical trials, and regulatory affairs, as well as global BD experts, enabling very efficient and rapid drug development and clinical progress, and direct pursuit of global licensing.

In particular, CEO Kwon Kyu-chan, who oversees new drug development, is one of Korea’s leading new drug development experts, having obtained multiple FDA approvals while at Hanmi Pharmaceutical. The bio-new drug for neutropenia treatment, Rolontis (US name, Rolvedon), led by CEO Kwon, achieved sales of 90 billion KRW last year in both the US and Korea. Given his professional experience in commercialization and license-out of new drugs, confidence in the success potential is also high.

DXVX’s research achievements are receiving significant attention in the industry. It is known that various domestic and international pharmaceutical and biotech companies are actively exploring diverse collaboration possibilities. The company plans to further accelerate the development of oral GLP-1 obesity treatments through various strategic cooperation options such as early license-out, global joint clinical trials, and research funding investments.